Herbal medicines: challenges in the modern world. Part 2. European Union and Russia
| Autor: | Michael I. Gubarev, Lubov V. Krepkova, Fenella Corrick, Valentina V. Bortnikova, Elena Y. Enioutina, Catherine M.T. Sherwin, Kathleen M. Job, Helen Sammons |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Economic growth medicine.medical_specialty Alternative medicine Herb-Drug Interactions law.invention Russia 03 medical and health sciences 0302 clinical medicine law medicine media_common.cataloged_instance Animals Humans Pharmacology (medical) European Union General Pharmacology Toxicology and Pharmaceutics European union media_common Herb-drug interactions Plants Medicinal Traditional medicine business.industry General Medicine Legislation Drug 030104 developmental biology 030220 oncology & carcinogenesis Dietary Supplements Russian federation Medicine Traditional Plant Preparations Phytotherapy business |
| Zdroj: | Expert review of clinical pharmacology. 9(8) |
| ISSN: | 1751-2441 |
| Popis: | Herbal medicines (HMs) have been well known to people of the European Union (EU) and Russia for centuries. Currently, Western HMs can be classified into two categories, plant-derived conventional medicines and dietary supplements. Interest to HMs has grown rapidly in all countries during the past two decades.The main goal of this review article is to present the history of HMs in the EU and Russia, forms of modern HMs, including Oriental Medicines that are popular among consumers of both countries. Additional discussion points comprise safety and adulteration issues associated with HMs, including regulatory changes and new legislative measures undertaken by the authorities. Materials available from legislative and governmental websites, PubMed and news media were used. Expert commentary: Due to cultural diversities in the EU and Russia, traditional HMs of other regions, particularly Chinese Traditional and Ayurvedic medicines, are also popular. Recently, dietary supplements containing multiple herbal and other natural products have flooded the EU and Russian markets. Pharmacovigilance in these markets is challenging in terms of establishing quality and safety of ingredients, determining efficacy, and defining risks of herb-herb and herb-drug interactions. Both the EU and Russia have introduced new legislation aimed to overcome these deficiencies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|